A prospective, comparative, randomized study on efficacy, safety of oral methotrexate vs oral tofacitinib in management of palmoplantar psoriasis.

PALMOPLANTAR PSORIASIS IS A PERSISTENT INFLAMMATORY SKIN CONDITION CHARACTERISIED BY THE APPEARANCE OF THICKENED SCALY PLAQUES ON THE PALMS AND SOLES. THE CONDITION IS OFTEN RESISTANT TO CONVENTIONAL TOPICAL TREATMENTS SIGNIFICANTLLY IMPACTING THE PATIENT’S QUALITY OF LIFE AND LEADING TO BOTH PHYSICAL DISCOMFORT AND SOCIAL STIGMA. THE VARIABILITY IN TREATMENT RESPONSE NECESSITATIES ONGOING REASEARCH INTO MORE EFFECTIVE THERAPEUTIC STRATAGIES.

THIS PROSPECTIVE, COMPARATIVE, RANDOMISED CLINICAL STUDY AIMS TO EVALUATE THE EFFICACY, SAFETY OF ORAL METHOTREXATE VS ORAL TOFACITINIB IN THE MANAGEMENT OF PALMOPLANTAR PSORIASIS. CONDUCTED IN THE DEPARTMENT OF DERMATOLOGY, VENEREOLOGY, LEPROLOGY AT A TERTIARY CARE CENTRE IN MAHARASHTRA, THE STUDY WILL ENLIST PATIENTS WHO MEET THE INCLUSION CRITERIA AND DIVIDE THEM INTO TWO TREATMENT GROUPS. GROUP A WILL RECEIVE ORAL METHOTREXATE, DOSED ACCORDING TO BODY WEIGHT FOR A PERIOD OF 12 WEEKS. GROUP B WILL BE GIVEN ORAL TOFACITINIB 5MG TWICE DAILY FOR THE SAME DURATION. THE PRIMARY OUTCOME WILL BE THE CHANGE IN MODIFIED PALMOPLANTAR PSORIASIS AREA AND SEVERITY SCORE ( MPPPASI ) FROM BASELINE TO THE END OF TREATMENT, WITH A FOLLOW UP PERIOD OF 3 MONTHS TO ASSESS THE DURABILITY OF CLINICAL RESPONSE AND TO MONITOR FOR POTENTIAL RECURRENCE OR SIDE EFFECTS.